×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
TECH – bio-techne corp (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
TECH
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
1/8
02:36 pm
tech
Bio-Techne: Recovery Likely Coming, But Is There Enough Re-Rating Potential? [Seeking Alpha]
Low
Report
Bio-Techne: Recovery Likely Coming, But Is There Enough Re-Rating Potential? [Seeking Alpha]
1/6
07:25 am
tech
Bio-Techne (NASDAQ:TECH) was downgraded by analysts at Evercore ISI from a "strong-buy" rating to a "hold" rating.
Low
Report
Bio-Techne (NASDAQ:TECH) was downgraded by analysts at Evercore ISI from a "strong-buy" rating to a "hold" rating.
1/5
08:42 am
tech
Bio-Techne (NASDAQ:TECH) was given a new $62.00 price target on by analysts at Evercore ISI.
Medium
Report
Bio-Techne (NASDAQ:TECH) was given a new $62.00 price target on by analysts at Evercore ISI.
1/5
08:22 am
tech
1 S&P 500 Stock with Exciting Potential and 2 We Question [Yahoo! Finance]
Medium
Report
1 S&P 500 Stock with Exciting Potential and 2 We Question [Yahoo! Finance]
12/23
07:00 am
tech
Bio-Techne to Present at the 2026 J.P. Morgan Healthcare Conference
Low
Report
Bio-Techne to Present at the 2026 J.P. Morgan Healthcare Conference
12/23
01:35 am
tech
Bio-Techne (TECH): Revisiting Valuation as Recent Gains Contrast a Weak One-Year Shareholder Return [Yahoo! Finance]
Low
Report
Bio-Techne (TECH): Revisiting Valuation as Recent Gains Contrast a Weak One-Year Shareholder Return [Yahoo! Finance]
12/19
05:59 am
tech
Bio-Techne (NASDAQ:TECH) was downgraded by analysts at Zacks Research from a "hold" rating to a "strong sell" rating.
Low
Report
Bio-Techne (NASDAQ:TECH) was downgraded by analysts at Zacks Research from a "hold" rating to a "strong sell" rating.
12/12
11:03 am
tech
Bio-Techne (NASDAQ:TECH) was given a new $72.00 price target on by analysts at Deutsche Bank Aktiengesellschaft.
Low
Report
Bio-Techne (NASDAQ:TECH) was given a new $72.00 price target on by analysts at Deutsche Bank Aktiengesellschaft.
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/14
12:21 pm
tech
Form SCHEDULE 13G/A BIO-TECHNE Corp Filed by: PRICE T ROWE ASSOCIATES INC /MD/
Low
Report
Form SCHEDULE 13G/A BIO-TECHNE Corp Filed by: PRICE T ROWE ASSOCIATES INC /MD/
11/5
04:47 pm
tech
Form 4 BIO-TECHNE Corp For: Nov 03 Filed by: Hippel James
Low
Report
Form 4 BIO-TECHNE Corp For: Nov 03 Filed by: Hippel James
11/5
04:47 pm
tech
Form 4 BIO-TECHNE Corp For: Nov 03 Filed by: Kelderman Kim
Low
Report
Form 4 BIO-TECHNE Corp For: Nov 03 Filed by: Kelderman Kim
11/5
04:46 pm
tech
Form 4 BIO-TECHNE Corp For: Nov 03 Filed by: Geist William
Low
Report
Form 4 BIO-TECHNE Corp For: Nov 03 Filed by: Geist William
11/5
04:32 pm
tech
Form 10-Q BIO-TECHNE Corp For: Sep 30
Low
Report
Form 10-Q BIO-TECHNE Corp For: Sep 30
11/5
06:31 am
tech
Form 8-K BIO-TECHNE Corp For: Oct 30
Medium
Report
Form 8-K BIO-TECHNE Corp For: Oct 30
11/3
05:38 pm
tech
Form 4 BIO-TECHNE Corp For: Oct 30 Filed by: Bushman Julie L
Low
Report
Form 4 BIO-TECHNE Corp For: Oct 30 Filed by: Bushman Julie L
11/3
05:38 pm
tech
Form 4 BIO-TECHNE Corp For: Oct 30 Filed by: KEEGAN JOSEPH D
Low
Report
Form 4 BIO-TECHNE Corp For: Oct 30 Filed by: KEEGAN JOSEPH D
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
4/1
BIO-TECHNE Corp (NASDAQ: TECH) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating.
12.5%
4/30 Q3/2020 3/31/2020 EPS 1.390 ZacksConsensus 1.010 ActVsEst 0.380 - Beat 6.1%
5/1 BIO-TECHNE Corp (NASDAQ: TECH) had its price target raised by analysts at Wells Fargo & Co from $190.00 to $220.00. They now have an "equal weight" rating on the stock. 5.7%
4/16 Bio-Techne Introduces RePlex Capabilities For Simple Western Assays On Jess™ 5.2%
11/14 BIO-TECHNE Corp (NASDAQ: TECH) is now covered by analysts at Stifel Nicolaus. They set a "buy" rating on the stock. 4.4%
3/30 Extracellular Vesicles From Plasma Have Higher Tumor RNA Fraction Than Platelets 4.0%
8/13 Bio-Techne And Cygnus Technologies Announce Partnership For 3G CHO-HCP Assay 3.6%
4/25 BIO-TECHNE Corp (NASDAQ: TECH) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. 3.5%
4/1 Dr. Roeland Nusse: Gairdner Award Recipient and Bio-Techne Board of Directors Member 2.9%
10/28 Bio-Techne Announces Investment For New GMP Manufacturing Facility 2.9%
4/30 Q3/2020 3/31/2020 EPS 1.390 ZacksConsensus 1.010 ActVsEst 0.380 - Beat 6.1%
5/1 BIO-TECHNE Corp (NASDAQ: TECH) had its price target raised by analysts at Wells Fargo & Co from $190.00 to $220.00. They now have an "equal weight" rating on the stock. 5.7%
4/16 Bio-Techne Introduces RePlex Capabilities For Simple Western Assays On Jess™ 5.2%
11/14 BIO-TECHNE Corp (NASDAQ: TECH) is now covered by analysts at Stifel Nicolaus. They set a "buy" rating on the stock. 4.4%
3/30 Extracellular Vesicles From Plasma Have Higher Tumor RNA Fraction Than Platelets 4.0%
8/13 Bio-Techne And Cygnus Technologies Announce Partnership For 3G CHO-HCP Assay 3.6%
4/25 BIO-TECHNE Corp (NASDAQ: TECH) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. 3.5%
4/1 Dr. Roeland Nusse: Gairdner Award Recipient and Bio-Techne Board of Directors Member 2.9%
10/28 Bio-Techne Announces Investment For New GMP Manufacturing Facility 2.9%
TOP News Decliners
3/20
BIO-TECHNE Corp (NASDAQ: TECH) had its price target lowered by analysts at Citigroup Inc from $225.00 to $175.00. They now have a "neutral" rating on the stock.
-4.6%
4/21 BIO-TECHNE Corp (NASDAQ: TECH) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. -3.4%
5/7 Form 10-Q BIO-TECHNE Corp For: Mar 31 -2.9%
3/6 Form 4 BIO-TECHNE Corp For: Mar 04 Filed by: Eansor Norman David -2.9%
3/18 Bio-Techne's Exosome Diagnostics Laboratory Announces Reimbursement Contract With General Services Administration -2.8%
8/6 Q4/2019 6/30/2019 EPS 1.250 ZacksConsensus 1.170 ActVsEst 0.080 - Beat -2.7%
2/27 Bio-Techne To Present At The Barclays Global Healthcare Conference -2.4%
10/8 Bio-Techne To Host Conference Call On October 29, 2019, To Announce First Quarter 2020 Financial Results -2.3%
2/24 Bio-Techne To Present At The Cowen 40th Annual Health Care Conference -2.2%
7/10 Form 4 BIO-TECHNE Corp For: Jul 08 Filed by: Kummeth Charles R. -2.1%
4/21 BIO-TECHNE Corp (NASDAQ: TECH) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. -3.4%
5/7 Form 10-Q BIO-TECHNE Corp For: Mar 31 -2.9%
3/6 Form 4 BIO-TECHNE Corp For: Mar 04 Filed by: Eansor Norman David -2.9%
3/18 Bio-Techne's Exosome Diagnostics Laboratory Announces Reimbursement Contract With General Services Administration -2.8%
8/6 Q4/2019 6/30/2019 EPS 1.250 ZacksConsensus 1.170 ActVsEst 0.080 - Beat -2.7%
2/27 Bio-Techne To Present At The Barclays Global Healthcare Conference -2.4%
10/8 Bio-Techne To Host Conference Call On October 29, 2019, To Announce First Quarter 2020 Financial Results -2.3%
2/24 Bio-Techne To Present At The Cowen 40th Annual Health Care Conference -2.2%
7/10 Form 4 BIO-TECHNE Corp For: Jul 08 Filed by: Kummeth Charles R. -2.1%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: